CML patient experience study on standard TKI therapy
Part of Blood & lymphatic, Cancer clinical trials.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have Philadelphia chromosome positive CML in chronic phase.
- You are taking one of these TKI medicines as your first or second line treatment: asciminib, bosutinib, dasatinib, imatinib, or nilotinib.
- You receive your care at a medical practice in the US or Puerto Rico.
- You agree to let the study access your anonymized medical records or claims data.
- You are not currently in a clinical trial that could change how your CML is managed.
- You are not taking a third or later line TKI, have a T315I mutation, are in treatment-free remission, or have had a stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy pill (TGRX-678) for adults with chronic-phase CML who no longer benefit from or cannot tolerate at least three other targeted therapies. The goal is to see if this drug can control the leukemia better.
This trial studies a new drug (KRT-232) combined with a standard CML “TKI” medicine to treat chronic myeloid leukemia (CML) that is resistant or not tolerated after at least one prior TKI. It may help people whose leukemia hasn’t controlled as expected on current treatments.
This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.
This trial looks at how well children with chronic myeloid leukemia (CML) respond to standard “TKI” tablets when treatment starts. It uses genetic test results from diagnosis (DNA/RNA) to understand which children respond better and why.
This trial looks at how a targeted therapy called TKI (tyrosine kinase inhibitor) affects thyroid function in patients newly diagnosed with chronic myeloid leukemia (CML). It aims to understand any changes in the thyroid gland during treatment.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
Hear when a new Chronic Myelogenous Leukemia - Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.